Division of Viral Products, Center for Biologics, Food and Drug Administration, Bldg29A/Rm1D10, 8800 Rockville Pike, Bethesda, MD 20892, USA; E-mail:
Viruses. 2009 Sep;1(2):144-65. doi: 10.3390/v1020144. Epub 2009 Aug 12.
Studies in patients and chimpanzees that spontaneously clear Hepatitis C Virus (HCV) have demonstrated that natural immunity to the virus is induced during primary infections and that this immunity can be cross protective. These discoveries led to optimism regarding prophylactic HCV vaccines and a number of studies in the chimpanzee model have been performed, all of which resulted in modified infections after challenge but did not always prevent persistence of the virus. Therapeutic vaccine strategies have also been pursued in an effort to reduce the costs and side effects associated with anti-viral drug treatment. This review summarizes the studies performed thus far in both patients and chimpanzees for prophylactic and therapeutic vaccination, assesses the progress made and future perspectives.
在自发性清除丙型肝炎病毒 (HCV) 的患者和黑猩猩身上进行的研究表明，原发性感染期间会诱导针对该病毒的天然免疫，并且这种免疫具有交叉保护作用。这些发现使人们对预防性 HCV 疫苗产生了乐观情绪，并在黑猩猩模型中进行了多项研究，所有这些研究在受到挑战后都导致了感染的改变，但并不总是能阻止病毒的持续存在。人们还寻求了治疗性疫苗策略，以努力降低抗病毒药物治疗相关的成本和副作用。这篇综述总结了迄今为止在患者和黑猩猩中进行的预防性和治疗性疫苗接种研究，评估了已取得的进展和未来展望。
